Related Experiment Video
Updated: Jun 1, 2026
12:03
Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector
Published on: October 31, 2012
Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution
Dennis L Cooper1, Kathryn Pratt, Julie Baker
1Section of Hematologic Malignancies, Yale Cancer Center, New Haven, CT, USA. dennis.cooper@yale.edu
Clinical Lymphoma, Myeloma & Leukemia
|June 11, 2011
Summary
Administering plerixafor 15 hours before apheresis effectively mobilizes stem cells, even for high-risk patients. This approach improves convenience and accessibility for stem cell collection in lymphoma and myeloma treatment.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- Plerixafor is approved for stem cell mobilization in non-Hodgkin lymphoma and multiple myeloma.
- Current 10 PM injection timing is inconvenient and requires specialized infrastructure.
Purpose of the Study:
- To evaluate the efficacy of plerixafor administered 15 hours prior to apheresis.
- To assess plerixafor's effectiveness in high-risk patients for stem cell mobilization.
Main Methods:
- Plerixafor was administered at 5 PM, with apheresis performed approximately 15 hours later.
- Study included patients with lymphoma and myeloma, focusing on those with prior mobilization failure or risk factors like lenalidomide therapy.
Main Results:
- 47 out of 48 patients successfully collected adequate stem cells (> 2 × 10E6 CD34+ cells/kg).
- All 13 patients with prior G-CSF mobilization failure and 18 patients treated with ≥4 cycles of lenalidomide achieved successful collection.
- 83% of patients with poor mobilization potential (pre-plerixafor CD34+ cells < 10/μL) had sufficient stem cells for transplant.
Conclusions:
- Plerixafor is effective when administered 15 hours before apheresis, even in high-risk populations.
- Suggests cost-effective use for patients inadequately mobilized by G-CSF alone or as salvage therapy.
